Portfolio review - september 19th

A lot of selling and buying has been made in the Penetrator portfolio in the last days of august. I was disapointed with the results of some of my companies, I saw other opportunities and I added to my position in some cases.

I sold all my shares of Mallinckrodt, Dorman Products and Cipher Pharma. I initiated a position in Allergan and Chicago Bridge and Iron. I bought more shares of a lot of companies. It's been a while since there was so much activity in the porfolio. In fact, I'm not sure there ever was so much activity in my portfolio.

At the moment, I think there's a lot of stocks that look attractive. Home Capital Goup is still pretty cheap, Callidus Capital is dirty cheap (and the last results were good, such as the 5% dividend recently initiated). I still believe a lot in Valeant and Corcordia Healthcare (they made a huge acquisition recently). In the US, Portfolio recovery, Gilead, Allergan and Chicago Bridge and Iron are cheap. Dollar Tree and Ross Stores are a more expensive, but their price is more fair now than it was a month ago.

Here's the Penetrator Portfolio:

Canadian stocks:

Valeant: 15,1%
Constellation Software: 10,8%
CGI Group: 8,7%
Alimentation Couche-Tard:  7,4%
Home Capital Group: 6,8%
Concordia Healthcare: 6,5%
Nobilis Health: 4%
Knight Therapeutics: 3,8%
Callidus Capital: 2,8%

US stocks: 

Portfolio Recovery and associates: 8,4%
Gilead: 8,3%
Allergan: 5,3%
Chicago Bridge and Iron: 3,8%
Dollar Tree: 3,6%
Ross Stores: 3,6%

Cash: 1,1%